{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:08:35Z","timestamp":1775747315164,"version":"3.50.1"},"reference-count":47,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the recent success of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, and the phosphoinositide-3-kinase (PI3K) inhibitor, idelalisib, in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL), a number of new agents targeting the B-cell receptor (BCR) pathway are in clinical development. In addition, multiple trials combining these agents with conventional cytotoxic chemotherapy, immunomodulatory agents, monoclonal antibodies, or other kinase inhibitors are underway. This review will summarize the current data with the use of single agent and combination therapy with BCR inhibitors in NHL. In addition, commonly encountered as well as serious toxicities and hypothesized resistance mechanisms will be discussed. Lastly, this review will examine the future of these agents and opportunities to maneuver them into the front-line setting in selected NHL subtypes.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.82","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"82-91","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["B-cell receptor pathway modulators in NHL"],"prefix":"10.1182","volume":"2015","author":[{"given":"Kristie A.","family":"Blum","sequence":"first","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111704503899300_B1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"2019111704503899300_B2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111704503899300_B3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"2019111704503899300_B4","article-title":"Single-agent ibrutinib demonstrates safety and durability of response at 2 years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open-label phase 2 study","volume":"124","author":"Wang","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B5","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"2019111704503899300_B6","article-title":"Poor overall survival of patients with ibrutinib-resistant mantle cell lymphoma","volume":"33","author":"Martin","year":"2015","journal-title":"Hematol Oncol"},{"issue":"6","key":"2019111704503899300_B7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"key":"2019111704503899300_B8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for pi3k inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"key":"2019111704503899300_B9","article-title":"Mutational analysis of patients with primary resistance to single-agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL)","volume":"124","author":"Balasubramanian","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B10","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"2019111704503899300_B11","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110\u03b1-mediated constitutive PI3K signaling limits the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"key":"2019111704503899300_B12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"2019111704503899300_B13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"2019111704503899300_B14","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed\/refractory de novo diffuse large B cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study","volume":"120","author":"Wilson","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol"},{"key":"2019111704503899300_B16","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.8553","article-title":"The bruton's tyrosine kinase inhibitor ONO-4059: single agent activity in patients with relapsed and refractory non-GCB DLBCL","volume":"32","author":"Dyer","year":"2014","journal-title":"J Clin Oncol"},{"key":"2019111704503899300_B17","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"25","author":"Robertson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111704503899300_B18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.371.371","article-title":"A phase III study of enzasturin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the Prelude trial","volume":"122","author":"Crump","year":"2013","journal-title":"Blood"},{"key":"2019111704503899300_B19","article-title":"Clinical safety and activity in a phase 1 trial of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-\u03b4, \u03b3, in patients with advanced hematologic malignancies","volume":"120","author":"Flinn","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B20","article-title":"An open-label phase ii study of buparlisib (BKM120) in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma","volume":"124","author":"Younes","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B21","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"2019111704503899300_B22","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"key":"2019111704503899300_B23","article-title":"Mature follow up from a phase 2 study of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-hodgkin lymphoma (iNHL)","volume":"124","author":"Gopal","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B24","article-title":"a Phase 1 evaluation of duvelisib (IPI-145), a PI3K-\u03b4,\u03b3 inhibitor, in patients with relapsed\/refractory iNHL","volume":"124","author":"Flinn","year":"2014","journal-title":"Ash Annual Meeting Abstracts"},{"key":"2019111704503899300_B25","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","author":"Coutre","journal-title":"Leuk Lymphoma"},{"key":"2019111704503899300_B26","article-title":"The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma","volume":"120","author":"Fowler","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B27","article-title":"Ibrutinib monotherapy in relapsed\/refractory follicular lymphoma (FL): preliminary results of a phase 2 consortium (P2C) trial","volume":"124","author":"Bartlett","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B28","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"2019111704503899300_B29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"key":"2019111704503899300_B30","article-title":"Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a phase ii clinical trial","volume":"124","author":"Wang","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B31","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"2019111704503899300_B32","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Nat Acad Sci U S A"},{"issue":"13","key":"2019111704503899300_B33","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood-2014-08-593137","article-title":"Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in syngeneic mouse lymphoma model","volume":"125","author":"Sagiv-Barfi","year":"2015","journal-title":"Blood"},{"key":"2019111704503899300_B34","article-title":"A phase i study of ibrutinib and lenalidomide in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma","volume":"124","author":"Christian","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.13149","article-title":"Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways","volume":"168","author":"Zhao","year":"2015","journal-title":"Br J Haematol"},{"key":"2019111704503899300_B36","article-title":"Durable responses following treatment with the PI3K-delta inhibitor idelalisib in combination with rituximab, bendamustine, or both, in recurrent indolent non-Hodgkin lymphoma: phase I\/II results","volume":"124","author":"de Vos","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B37","article-title":"An open-label, phase Ib study of duvelisib (IPI-145) in combination with bendamustine, rituximab or bendamustine\/rituximab in select subjects with lymphoma or chronic lymphocytic leukemia","volume":"124","author":"Flinn","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B38","article-title":"Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed\/refractory B cell lymphomas: Alliance A051201 and A051202","volume":"124","author":"Smith","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cpt.65","article-title":"Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas","volume":"97","author":"Alinari","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"2019111704503899300_B40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/annonc\/mdm463","article-title":"A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma","volume":"19","author":"Morschhauser","year":"2008","journal-title":"Ann Oncol"},{"key":"2019111704503899300_B41","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"2019111704503899300_B42","article-title":"A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","volume":"124","author":"Flinn","year":"2014","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/bjh.12853","article-title":"Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma","volume":"166","author":"Schwartzberg","year":"2014","journal-title":"Br J Hematol"},{"key":"2019111704503899300_B44","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1158\/1078-0432.CCR-12-0181","article-title":"A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstr\u00f6m macroglobulinemia","volume":"18","author":"Ghobrial","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2019111704503899300_B45","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8032","article-title":"Phase 1b trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (BTK), in chronic lymphocytic leukemia and B-non-Hodgkin lymphoma","volume":"30","author":"Brown","year":"2012","journal-title":"J Clin Oncol"},{"key":"2019111704503899300_B46","article-title":"Update on the safety and efficacy of the pan class I PI3K inhibitor SAR245408 (XL147) in chronic lymphocytic leukemia and non-Hodgkin's lymphoma patients","volume":"122","author":"Brown","year":"2013","journal-title":"ASH Annual Meeting Abstracts"},{"key":"2019111704503899300_B47","article-title":"Phase 2 trial of entospletinib (GS-9973), a selective SYK inhibitor, in follicular lymphoma (FL)","volume":"124","author":"Sharman","year":"2014","journal-title":"ASH Annual Meeting Abstracts"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/82\/1251470\/bep00115000082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/82\/1251470\/bep00115000082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T01:51:54Z","timestamp":1601085114000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/82\/20757\/Bcell-receptor-pathway-modulators-in-NHL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.82","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}